PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis

BACKGROUND: Flixabi(TM) (SB2) is a biosimilar of the reference infliximab (IFX), Remicade(®). Published evidence on long-term, real-world use of SB2 in patients either IFX naive or transitioned from prior IFX is scarce. OBJECTIVES: We evaluated persistence, effectiveness, and safety of SB2 over 12 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouhnik, Yoram, Fautrel, Bruno, Beaugerie, Laurent, Pelletier, Anne-Laure, Martinez-Vinson, Christine, Freudensprung, Ulrich, Brigui, Amira, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021102/
https://www.ncbi.nlm.nih.gov/pubmed/36936799
http://dx.doi.org/10.1177/17562848221145654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021102/
https://www.ncbi.nlm.nih.gov/pubmed/36936799
http://dx.doi.org/10.1177/17562848221145654

Ejemplares similares